Study guide

8.3 Interstitial Lung Disease & Sarcoidosis

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

8.3 Interstitial Lung Disease & Sarcoidosis

Key Takeaways Explain This Topic AI

Idiopathic Pulmonary Fibrosis (IPF) characteristically affects men over 60 years and presents with bibasal fine end-inspiratory 'Velcro' crackles, clubbing, restrictive spirometry with severely reduced TLCO, and a definitive UIP pattern on HRCT (subpleural honeycombing and traction bronchiectasis).

Antifibrotic therapies (pirfenidone and nintedanib) are recommended by NICE for IPF patients with an FVC of 50-80% predicted; they halve the annual rate of lung function decline, while immunosuppression (steroids/azathioprine) increases mortality.

Connective tissue disease-associated ILD typically produces a non-specific interstitial pneumonia (NSIP) pattern on HRCT (ground-glass opacities with subpleural sparing), except rheumatoid arthritis which characteristically causes a UIP pattern.

Hypersensitivity pneumonitis is distinguished by mid-to-upper zone ground-glass opacities, mosaic attenuation with expiratory air trapping, and striking bronchoalveolar lavage (BAL) lymphocytosis exceeding 40-50% with an inverted CD4:CD8 ratio.

Löfgren's syndrome (erythema nodosum, bilateral hilar lymphadenopathy, and migratory polyarthritis) carries an excellent prognosis with spontaneous resolution (>80%), while sarcoid hypercalcaemia results from autonomous 1-alpha-hydroxylase expression by granuloma macrophages converting 25-OH-D to 1,25-(OH)2-D.

Last updated: September 2026

Interstitial lung diseases (ILDs) encompass a diverse group of over 200 non-neoplastic conditions affecting the alveolar epithelium, pulmonary capillary endothelium, and surrounding perialveolar mesenchymal tissue. For MRCP(UK) Part 1, candidates must master the diagnostic features of Idiopathic Pulmonary Fibrosis (IPF), distinguishing features of secondary connective tissue and drug-induced ILDs, the immunological and bronchoalveolar profile of hypersensitivity pneumonitis, and the multifaceted clinical, biochemical, and radiological spectrum of sarcoidosis.

1. Idiopathic Pulmonary Fibrosis (IPF)

IPF is a specific, chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults and limited strictly to the lungs. It is associated with the histopathological and radiological pattern of Usual Interstitial Pneumonia (UIP) .

Pathogenesis & Epidemiology

Demographics: Male predominance (approx. 2:1), typical age > 60 years > 60\text{ years} > 60 years ; strong association with active or prior cigarette smoking (relative risk ~1.6), environmental dust exposures (metal, wood, silica), chronic microaspiration secondary to gastro-oesophageal reflux disease (GERD), and genetic variants (e.g., M U C 5 B MUC5B M U C 5 B promoter polymorphism, telomerase reverse transcriptase [ T E R T / T E R C TERT/TERC TERT / TERC ] mutations).

Mechanism: Repetitive subclinical microinjury to alveolar epithelial type II cells leads to aberrant epithelial-mesenchymal crosstalk. Instead of normal physiological re-epithelialization, exuberant production of pro-fibrotic mediators (transforming growth factor-beta [TGF- β \beta β ], platelet-derived growth factor [PDGF], fibroblast growth factor [FGF]) drives persistent myofibroblast proliferation and excessive extracellular matrix deposition. Progressive parenchymal architectural distortion causes lung honeycombing, loss of capillary gas exchange units, and refractory hypoxaemia.

Clinical Presentation & Examination

Symptoms: Insidious onset of progressive exertional breathlessness and an intractable, dry, non-productive hacking cough lasting months to years.

Signs:

Bilateral fine, bibasal, end-inspiratory 'Velcro' crackles: Auscultated predominantly at the posterior lung bases; characteristically persist after coughing (unlike secretions in bronchitis).

Digital clubbing: Present in 50 – 70 % 50\text{–}70\% 50 – 70% of patients.

Late signs: Central cyanosis, loud pulmonary second sound ( P 2 P_2 P 2 ​ ), peripheral oedema, and right ventricular heave reflecting secondary pulmonary hypertension and cor pulmonale.

High-Resolution Computed Tomography (HRCT): The UIP Pattern

Thin-slice ( 1 mm 1\text{ mm} 1 mm ) volumetric HRCT of the chest is the central diagnostic imaging modality. In an appropriate clinical context, a Definite UIP pattern on HRCT precludes the necessity of an invasive surgical lung biopsy.

Hallmark Features of UIP:

Subpleural and basal predominance: Fibrosis is concentrated along the periphery of the lower lung zones.

Reticular opacities: Interlobular and intralobular septal thickening.

Traction bronchiectasis and bronchiolectasis: Irregular bronchial dilation caused by fibrous parenchymal retractile forces.

Honeycombing: Clustered, thick-walled, cystic airspaces ( 3 – 10 mm 3\text{–}10\text{ mm} 3 – 10 mm ) arranged in multiple layers beneath the pleura.

Absence of inconsistent/atypical features: No extensive ground-glass opacities exceeding reticulation, no profuse micronodules, no mosaic perfusion or air trapping, and no peribronchovascular predominance.

Pulmonary Function Tests (PFTs)

Restrictive Ventilatory Defect: Reduced Forced Vital Capacity ( FVC < 80 % \text{FVC} < 80\% FVC < 80% predicted) and Total Lung Capacity ( TLC < 80 % \text{TLC} < 80\% TLC < 80% predicted).

Preserved/Elevated Ratio: FEV 1 / FVC ≥ 0.75 – 0.85 \text{FEV}_1/\text{FVC} \ge 0.75\text{–}0.85 FEV 1 ​ / FVC ≥ 0.75 – 0.85 (proportional reduction in both parameters, or higher due to increased radial parenchymal tethering).

Transfer Factor: Disproportionate, profound reduction in the transfer factor for carbon monoxide ( TLCO \text{TLCO} TLCO ) and transfer coefficient ( KCO \text{KCO} KCO ), indicating alveolar-capillary barrier destruction.

Desaturation: Significant drop in SpO 2 \text{SpO}_2 SpO 2 ​ during the 6-minute walk test (6MWT).

Evidence-Based Antifibrotic Pharmacotherapy

Landmark clinical trials (ASCEND and INPULSIS) established that antifibrotic agents halve the annual rate of FVC decline (~ 100 mL/year 100\text{ mL/year} 100 mL/year reduction in loss), decreasing disease progression and acute exacerbations, though they do not reverse established fibrotic scarring.

NICE Eligibility Criteria: Initiated only in confirmed IPF when baseline FVC \text{FVC} FVC is between 50 % 50\% 50% and 80 % 80\% 80% predicted .

Pirfenidone: Oral pyridone with antifibrotic and anti-inflammatory mechanisms; inhibits TGF- β \beta β synthesis and collagen production. Adverse effects: Marked cutaneous photosensitivity, rash, nausea, dyspepsia, and elevated liver enzymes.

Nintedanib: Oral intracellular tyrosine kinase inhibitor blocking vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). Adverse effects: Severe diarrhoea ( > 60 % > 60\% > 60% of patients), abdominal cramping, and hepatotoxicity.

Contraindicated Regimens: Immunosuppressive therapy with high-dose corticosteroids, azathioprine, and N-acetylcysteine was evaluated in the landmark PANTHER-IPF trial ; it was terminated early due to significantly increased mortality and hospitalization rates. Immunosuppression must never be used in IPF.

  • 2. Secondary Interstitial Lung Diseases & Hypersensitivity Pneumonitis
  • Connective Tissue Disease-Associated ILD (CTD-ILD)

Systemic Sclerosis (SSc): ILD complicates up to 80 % 80\% 80% of systemic sclerosis (predominantly diffuse cutaneous SSc with anti-topoisomerase I / anti-Scl-70 antibodies ). The characteristic HRCT pattern is Non-Specific Interstitial Pneumonia (NSIP) , defined by symmetrical, bibasal ground-glass opacities with fine reticulation, traction bronchiectasis, and characteristic subpleural sparing (absence of peripheral honeycombing).

Rheumatoid Arthritis (RA-ILD): Affects older men with active erosive disease, high-titre Rheumatoid Factor, and anti-cyclic citrullinated peptide (anti-CCP). Uniquely among CTDs, RA-ILD most commonly produces a UIP pattern (honeycombing) indistinguishable from IPF.

Antisynthetase Syndrome: Autoimmune myopathy characterized by antibodies directed against aminoacyl-tRNA synthetases (most commonly anti-Jo-1 [histidyl-tRNA synthetase]). The clinical pentad includes:

Rapidly progressive, aggressive interstitial lung disease (NSIP or organizing pneumonia pattern).

Inflammatory myositis (proximal muscle weakness, elevated creatine kinase).

"Mechanic's hands": Hyperkeratotic, fissured, cracked, hyperpigmented scaling along the radial margins of the fingers.

Symmetrical non-erosive inflammatory polyarthritis.

Raynaud's phenomenon and unexplained fevers.

Drug-Induced Interstitial Lung Diseases

Amiodarone: Accumulates within alveolar macrophages, producing characteristic foamy, vacuolated macrophages with lamellar inclusion bodies on cytology. Presents with subacute cough, breathlessness, and high-attenuation consolidation or ground-glass infiltrates on CT due to high iodine content. Discontinuation and corticosteroid therapy are required.

Bleomycin: Induces direct DNA strand breakage and reactive oxygen species generation, causing acute pulmonary toxicity in up to 10 % 10\% 10% . Risk multiplies with cumulative dose ( > 400 , 000 units > 400,000\text{ units} > 400 , 000 units ), impaired renal excretion, and exposure to high fractional inspired oxygen concentrations ( FiO 2 \text{FiO}_2 FiO 2 ​ ) during general anaesthesia.

Methotrexate: Causes acute/subacute hypersensitivity pneumonitis (fever, dry cough, peripheral eosinophilia in 50 % 50\% 50% , diffuse ground-glass opacities); typically responds rapidly to drug cessation and corticosteroids.

Nitrofurantoin: Acute presentation resembles an acute allergic reaction (fever, dyspnoea, peripheral eosinophilia, bilateral infiltrates, pleural effusions within hours to days); chronic presentation produces insidious bibasal fibrosis resembling IPF following months of urinary tract prophylaxis.

Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis)

An immunologically mediated inflammatory reaction affecting the terminal bronchioles and alveolar interstitium following repeated inhalation of organic aeroantigens or chemical haptens in sensitized individuals. Combines Type III (immune complex / Arthus reaction) and Type IV (cell-mediated delayed-type) hypersensitivity.

Clinical Entity Specific Culprit Aeroantigen Source / Exposure Setting

Farmer's Lung Saccharopolyspora rectivirgula (formerly Micropolyspora faeni ), Thermoactinomyces vulgaris Mouldy hay, stored grain, damp silage

Bird Fancier's / Breeder's Lung Avian serum proteins, mucin, blooms Pigeon/budgerigar droppings, feather bloom, parakeet plumage

Humidifier / Air-Conditioner Lung Thermophilic actinomycetes, Acanthamoeba Contaminated residential humidifiers, ventilation systems

  • Malt Worker's Lung Aspergillus clavatus Mouldy malted barley
  • Cheese Washer's Lung Penicillium roqueforti Mouldy cheese storage cellars

HRCT Hallmark Features: Mid-to-upper lung zone predilection; poorly defined centrilobular ground-glass micronodules; mosaic attenuation; and expiratory lobular air trapping. The co-existence of normal parenchyma, ground-glass opacity, and air trapping produces the pathognomonic "three-density pattern" (formerly "headcheese sign").

Bronchoalveolar Lavage (BAL): Demonstrates marked lymphocytosis ( > 40 – 50 % > 40\text{–}50\% > 40 – 50% lymphocytes) with a decreased or inverted CD4:CD8 ratio ( < 1.0 < 1.0 < 1.0 ) , sharply differentiating it from sarcoidosis.

Management: Strict, absolute avoidance of the inciting antigen is curative in acute/subacute disease. Systemic corticosteroids (oral prednisolone) hasten resolution of acute inflammatory infiltrates.

3. Sarcoidosis: Multisystem Granulomatous Disease

Sarcoidosis is a multisystem, systemic inflammatory disease of unknown aetiology characterized by the formation of non-caseating epithelioid-cell granulomas in affected organs, most prominently the lungs, intrathoracic lymph nodes, eyes, and skin. It arises from an exaggerated cell-mediated Th1 immune response driven by interleukin-2 (IL-2), interferon-gamma (IFN- γ \gamma γ ), and tumour necrosis factor-alpha (TNF- α \alpha α ).

Clinical Syndromes & Extrapulmonary Manifestations

Löfgren's Syndrome: A classic acute, self-limiting clinical presentation characterized by the triad of:

Erythema nodosum: Painful, violaceous, tender subcutaneous nodules along the extensor surfaces of the lower legs.

Bilateral hilar lymphadenopathy (BHL): Symmetrical, well-demarcated hilar and paratracheal node enlargement on chest radiography.

Migratory polyarthritis / periarthritis: Predominantly involving the ankles and knees, accompanied by fever.

Prognosis: Outstanding; > 80 – 90 % > 80\text{–}90\% > 80 – 90% experience spontaneous complete resolution within 1 to 2 years without long-term sequelae. First-line management comprises non-steroidal anti-inflammatory drugs (NSAIDs); corticosteroids are rarely required.

Heerfordt's Syndrome (Uveoparotid Fever): Characterized by uveitis (anterior or posterior), parotid gland enlargement, facial nerve palsy (lower motor neuron Bell's palsy), and low-grade pyrexia.

Organ-Specific Involvement:

Cutaneous: Lupus pernio (violaceous indurated plaques across the nose, cheeks, and earlobes; strongly correlates with chronic, refractory pulmonary disease and poor prognosis), maculopapular sarcoid, subcutaneous nodules.

Ocular: Anterior uveitis, chronic granulomatous panuveitis, retinal vasculitis, conjunctival nodules (mandates routine slit-lamp examination).

Neurological (Neurosarcoidosis): Cranial nerve palsies (cranial nerve VII most frequent), lymphocytic aseptic meningitis, hypothalamic-pituitary dysfunction (diabetes insipidus, hyperprolactinaemia), peripheral neuropathy.

Cardiac: Myocardial granulomatous infiltration causing ventricular tachyarrhythmias, complete heart block, sudden cardiac death, and dilated cardiomyopathy.

Scadding Chest Radiographic Staging

Stage Chest Radiograph Features Approximate Spontaneous Resolution Rate

Stage 0 Normal chest radiograph (occurs in 5 – 10 % 5\text{–}10\% 5 – 10% of patients with isolated extrapulmonary disease) N/A

Stage I Bilateral Hilar Lymphadenopathy (BHL) alone without parenchymal infiltrates 60 – 80 % 60\text{–}80\% 60 – 80% spontaneous resolution

Stage II Bilateral Hilar Lymphadenopathy PLUS diffuse parenchymal lung infiltrates 50 – 60 % 50\text{–}60\% 50 – 60% spontaneous resolution

Stage III Diffuse parenchymal infiltrates WITHOUT bilateral hilar lymphadenopathy 30 % 30\% 30% spontaneous resolution

Stage IV Extensive irreversible pulmonary fibrosis (upper zone traction bronchiectasis, honeycombing, volume loss) 0 % 0\% 0% (permanent architectural distortion)

Calcium Metabolism & Biochemical Markers

Hypercalcaemia (approx. 10 % 10\% 10% ) & Hypercalciuria (approx. 30 % 30\% 30% ):

Epithelioid macrophages within non-caseating sarcoid granulomas independently and autonomously express 1 α 1\alpha 1 α -hydroxylase (CYP27B1) .

This enzyme converts inactive circulating 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D (calcitriol) independent of parathyroid hormone (PTH).

Elevated calcitriol promotes hyperabsorption of calcium in the small intestine and stimulates osteoclastic bone resorption.

Laboratory profile: Elevated corrected serum calcium, suppressed serum PTH ( < 1.0 pmol/L < 1.0\text{ pmol/L} < 1.0 pmol/L ), elevated 1,25-(OH) 2 _2 2 ​ -vitamin D , and hypercalciuria (predisposing to nephrocalcinosis, nephrolithiasis, and chronic renal failure).

Serum Angiotensin-Converting Enzyme (ACE): Secreted by granuloma epithelioid cells; elevated in ~60% of patients with active sarcoidosis. Lacks diagnostic specificity (elevated in TB, silicosis, Gaucher's disease, hyperthyroidism) but serves as an adjunctive marker to track disease activity.

Bronchoalveolar Lavage (BAL): Reveals marked CD4+ T-cell lymphocytosis with a characteristically elevated CD4:CD8 ratio ( > 3.5 > 3.5 > 3.5 ) , opposite to hypersensitivity pneumonitis.

Indications for Systemic Corticosteroid Therapy

Asymptomatic Stage I or stable Stage II sarcoidosis does not require immunosuppression. Definite indications for systemic corticosteroids (oral prednisolone 20 – 40 mg 20\text{–}40\text{ mg} 20 – 40 mg daily, followed by slow titration) include:

Symptomatic or severe hypercalcaemia / hypercalciuria with impaired renal function.

Cardiac sarcoidosis (conduction blocks, arrhythmias, cardiomyopathy).

Neurosarcoidosis (cranial palsies, meningitis, optic neuritis).

Active ocular disease refractory to topical therapy.

Disfiguring cutaneous lesions ( lupus pernio ).

Progressive, disabling pulmonary symptoms accompanied by deteriorating lung function (drop in FVC > 10 % > 10\% > 10% or TLCO > 15 % > 15\% > 15% ) or worsening Stage II/III parenchymal infiltrates.

4. Comprehensive Comparison of Interstitial Lung Diseases

Disease Entity Demographics & Predisposing Factors HRCT Distribution & Hallmarks Bronchoalveolar Lavage (BAL) Profile Primary Pharmacological Strategy

Idiopathic Pulmonary Fibrosis (IPF) Males > 60 years > 60\text{ years} > 60 years ; smokers; microaspiration / GERD Subpleural, basal predominance ; reticulation, traction bronchiectasis, honeycombing ; absent atypical features Predominantly neutrophilic ( > 5 % > 5\% > 5% ); normal/low lymphocytes Antifibrotics: Pirfenidone or Nintedanib (FVC 50 – 80 % 50\text{–}80\% 50 – 80% ); immunosuppression contraindicated

Non-Specific Interstitial Pneumonia (NSIP) Middle-aged females; strongly associated with connective tissue diseases (SSc, myositis) Basal, symmetrical ; diffuse ground-glass attenuation, fine reticulation, subpleural sparing ; rare honeycombing Moderate lymphocytosis ( 15 – 30 % 15\text{–}30\% 15 – 30% ); variable CD4:CD8 Systemic corticosteroids plus immunosuppression (mycophenolate mofetil or azathioprine)

Hypersensitivity Pneumonitis (HP) Exposure to bird antigens, mouldy hay, humidifiers; non-smokers Mid-to-upper zone predominance ; centrilobular ground-glass nodules, mosaic attenuation, air trapping ( three-density pattern ) Striking marked lymphocytosis ( > 40 – 50 % > 40\text{–}50\% > 40 – 50% ) with inverted CD4:CD8 ratio ( < 1.0 < 1.0 < 1.0 ) Strict antigen avoidance (curative); oral corticosteroids for acute inflammatory flares

Sarcoidosis Young adults 20 – 40 years 20\text{–}40\text{ years} 20 – 40 years & 50 – 65 years 50\text{–}65\text{ years} 50 – 65 years ; Afro-Caribbean / Scandinavian Peribronchovascular & upper/mid-zone ; perilymphatic nodules, symmetrical BHL; Stage IV fibrosis CD4+ lymphocytosis with elevated CD4:CD8 ratio ( > 3.5 > 3.5 > 3.5 ) Observation for Löfgren's / asymptomatic; oral prednisolone for hypercalcaemia, cardiac, neuro, or eye disease

Cryptogenic Organizing Pneumonia (COP) Age 50 – 60 years 50\text{–}60\text{ years} 50 – 60 years ; subacute flu-like illness Subpleural or peribronchovascular bilateral consolidations (often migratory/fleeting); reverse halo (atoll) sign Mixed cellularity (lymphocytes, neutrophils, and eosinophils) Oral corticosteroids (prednisolone 0.75 – 1.0 mg/kg/day 0.75\text{–}1.0\text{ mg/kg/day} 0.75 – 1.0 mg/kg/day ); rapid clinical response